Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/32810
Title: A multi-institutional evaluation of carboplatin plus docetaxel combination in elderly patients with advanced gastric cancer
Authors: Karabulut, Bülent
Özdemir, Feyyaz
Tunalı, Didem
Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.
Uludağ Üniversitesi/Veterinerlik Fakültesi/Radyasyon Onkolojisi Anabilim Dalı.
0000-0003-1637-910X
0000-0002-9732-5340
Kurt, Ender
Çubukçu, Erdem
Ölmez, Ömer Fatih
Kurt, Meral
Avcı, Nilüfer
Evrensel, Türkkan
Manavoǧlu, Osman
AAJ-1027-2021
AAA-3961-2020
7006207332
53986153800
26435400000
8843050600
55390409800
6603942124
6602587152
Keywords: Oncology
Carboplatin
Docetaxel
Elderly
Gastric cancer
Phase-II trial
1st-line chemotherapy
Systemic treatment
RAndomized-trial
Cisplatin
Oxaliplatin
Fluorouracil
Adenocarcinoma
Paclitaxel
Older
Issue Date: 2013
Publisher: Imprimatur Publications
Citation: Kurt, E. vd. (2013). “A multi-institutional evaluation of carboplatin plus docetaxel combination in elderly patients with advanced gastric cancer”. Journal of BUON, 18(1), 147-153.
Abstract: Purpose: Albeit the majority of gastric cancers occur at advanced age, little is known regarding the optimal systemic treatment of elderly patients with advanced gastric cancer (AGC). Methods: Patients with AGC who were >= 65 years old and were treated with carboplatin (area under the curve/AUG 5, on day 1, every 3 weeks) plus docetaxel (75 mg/m(2), on day 1, every 3 weeks) at 3 institutions were included in this retrospective analysis. The efficacy and the safety data of the regimen were analyzed. Results: A total of 30 patients were enrolled. They received 128 cycles of chemotherapy, with a median of 4 cycles (range 2-8). Complete response (CR) and partial response (PR) were observed in 2 (6.7%) and 10 patients (33.3%), respectively, amounting to an overall objective response rate (ORR) of 40%. Seven patients (23.3%) had disease stabilization (SD), and 11(36.7%) showed disease progression (PD). The most common grade 3-4 toxicity was neutropenia occurring in 19 patients (63.3%). The mean progression-free survival (PFS) was 6.0 +/- 0.5 months (95% CI: 5.0-7.4), and the mean overall survival (OS) 12.0 +/- 1.0 months (95% CI: 9.2-12.1). Conclusion: Carboplatin plus docetaxel seems to be an active and well-tolerated regimen, representing a valuable alternative to cisplatin- and/or fluoropyrimidine-containing regimens for the treatment of elderly patients with AGC.
URI: http://hdl.handle.net/11452/32810
ISSN: 1107-0625
2241-6293
Appears in Collections:Scopus
Web of Science

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.